Metacrine, Inc. (MTCR) Stock Analysis
DELISTED 2023
What happened to Metacrine, Inc. (MTCR) stock?
Metacrine, Inc. (MTCR) no longer trades on public markets. It was delisted in June 2023. The figures below are historical and are not a current quote.
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Metacrine, Inc. (MTCR) trades at $0.5814. Metacrine, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for gastrointestinal diseases. Their lead product candidate, MET642, is in development for the treatment of ulcerative colitis. Sector: Healthcare.
Last analyzed: May 9, 2026Analyst Coverage for MTCR: MTCR does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates MTCR against Healthcare peers across nine fundamental dimensions and assigns a neutral fundamental signal based on the underlying data.
MTCR: 1/2 scored disciplines lean bearish. Dominant signal: Ray Dalio bullish.
How is this calculated? →Metacrine, Inc. (MTCR) Healthcare & Pipeline Overview
Metacrine, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing therapies for gastrointestinal diseases, with a primary focus on ulcerative colitis. Their lead candidate, MET642, has completed Phase I clinical trials, positioning the company within the competitive biotechnology landscape.
What Is the Investment Thesis for MTCR?
Metacrine, Inc. presents a focused investment opportunity within the biotechnology sector, specifically targeting gastrointestinal diseases. The company's lead candidate, MET642, has completed Phase I clinical trials for ulcerative colitis, representing a key value driver. Successful progression through further clinical trials and eventual commercialization of MET642 could significantly increase the company's value. However, the company's reliance on a single lead candidate introduces risk, as clinical trial outcomes are inherently uncertain. The company's small size and limited resources also pose challenges in competing with larger, more established pharmaceutical companies. The company's beta is -0.74. Continued monitoring of clinical trial results and financial performance is essential for assessing the investment viability.
Based on FMP financials and quantitative analysis
MTCR Key Highlights
Metacrine, Inc. is a clinical-stage biopharmaceutical company focused on gastrointestinal diseases.
- Lead product candidate MET642 has completed Phase I clinical trials for ulcerative colitis.
- The company was incorporated in 2014 and is headquartered in San Diego, California.
- Metacrine has a team of 10 employees.
- The company does not currently pay a dividend.
Who Are MTCR's Competitors?
MTCR is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| VRTX Vertex Pharmaceuticals Incorporated | $540.26 | -2.14% | $137B | 98 |
| REGN Regeneron Pharmaceuticals, Inc. | $835.15 | -0.68% | $86.0B | 94 |
| ALNY Alnylam Pharmaceuticals, Inc. | $229.30 | -5.49% | $30.7B | 92 |
| RPRX Royalty Pharma plc | $60.58 | -1.86% | $26.9B | 75 |
| INCY Incyte Corporation | $127.80 | -0.53% | $25.9B | 99 |
| UTHR United Therapeutics Corporation | $520.23 | -1.68% | $22.1B | 98 |
| NBIX Neurocrine Biosciences, Inc. | $153.42 | -1.37% | $15.4B | 93 |
| EXEL Exelixis, Inc. | $53.69 | -1.29% | $13.5B | 98 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are MTCR's Key Strengths?
Focus on a specific therapeutic area (gastrointestinal diseases).
- Lead product candidate (MET642) has completed Phase I clinical trials.
- Experienced management team with expertise in drug development.
- Located in a biotechnology hub (San Diego, California).
What Are MTCR's Weaknesses?
Limited financial resources compared to larger pharmaceutical companies.
- Reliance on a single lead product candidate.
- Small number of employees (10).
- Early-stage clinical development (Phase I).
What Could Drive MTCR Stock Higher?
Announcement of Phase II clinical trial results for MET642 in ulcerative colitis.
- Enrollment and progress in ongoing clinical trials for MET642.
- Potential for strategic partnerships with larger pharmaceutical companies.
What Are the Key Risks for MTCR?
Financial-distress signal — its Altman Z-Score of -5.64 sits in the distress zone (elevated bankruptcy risk).
- Negative return on equity (-83.5%) — the business is not currently generating profit on shareholder capital.
- Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
- Clinical trial failures for MET642.
- Regulatory delays or rejection of MET642.
- Competition from established pharmaceutical companies with existing GI therapies.
- Difficulty in securing funding to support clinical development programs.
What Are the Growth Opportunities for MTCR?
- Advancement of MET642 through Clinical Trials: The successful completion of Phase II and Phase III clinical trials for MET642 in ulcerative colitis represents a significant growth opportunity for Metacrine. Positive trial results could lead to regulatory approval and commercialization, potentially capturing a share of the multi-billion dollar ulcerative colitis market. The timeline for this growth opportunity is dependent on the duration of the clinical trials and the regulatory review process, potentially spanning several years.
- Expansion of Pipeline: Metacrine has the opportunity to expand its pipeline by identifying and developing additional therapies for other gastrointestinal diseases. This could involve in-licensing promising drug candidates or initiating internal research and development programs. A diversified pipeline would reduce the company's reliance on MET642 and enhance its long-term growth prospects. The timeline for this growth opportunity is dependent on the company's ability to secure funding and identify suitable drug candidates.
- Strategic Partnerships: Metacrine could pursue strategic partnerships with larger pharmaceutical companies to accelerate the development and commercialization of its therapies. These partnerships could provide access to funding, expertise, and distribution networks, enhancing Metacrine's ability to compete in the market. The timeline for this growth opportunity is dependent on the company's ability to attract and secure partnerships with suitable companies.
- Geographic Expansion: Upon successful commercialization of its therapies, Metacrine could expand its geographic reach beyond the United States. This could involve entering into licensing agreements with companies in other countries or establishing its own commercial operations. Geographic expansion would increase the company's potential market and revenue. The timeline for this growth opportunity is dependent on the company's ability to secure regulatory approvals and establish a commercial presence in new markets.
- Personalized Medicine Approaches: Metacrine could explore personalized medicine approaches to identify patients who are most likely to respond to its therapies. This could involve developing diagnostic tests to identify biomarkers that predict treatment response. Personalized medicine approaches could improve the efficacy of Metacrine's therapies and enhance its competitive advantage. The timeline for this growth opportunity is dependent on the company's ability to develop and validate diagnostic tests.
What Are MTCR's Competitive Advantages?
- Intellectual property protection through patents on its drug candidates.
- Clinical trial data demonstrating safety and efficacy.
- Specialized expertise in gastrointestinal disease biology and drug development.
- First-mover advantage in developing novel therapies for specific GI indications.
What Does MTCR Do?
Metacrine, Inc., established in 2014 and headquartered in San Diego, California, is a clinical-stage biopharmaceutical company dedicated to the discovery and development of innovative therapies for patients suffering from gastrointestinal (GI) diseases. The company's primary focus is on addressing unmet medical needs in conditions such as ulcerative colitis. Metacrine's lead product candidate, MET642, represents their most advanced program, having successfully completed Phase I clinical trials. This positions Metacrine as a player in the competitive GI therapeutics market, striving to bring novel treatment options to patients. Metacrine's research and development efforts are centered on identifying and developing therapies that can improve the lives of individuals affected by debilitating GI disorders. The company's strategy involves advancing MET642 through clinical development, with the goal of demonstrating its efficacy and safety in treating ulcerative colitis. By focusing on GI diseases, Metacrine aims to address a significant area of unmet medical need and establish itself as a key contributor in the biotechnology sector. The company's operations are based in San Diego, a hub for biotechnology innovation, providing access to talent and resources crucial for its growth and development.
What Products and Services Does MTCR Offer?
- Develops therapies for gastrointestinal diseases.
- Focuses on ulcerative colitis treatment.
- Conducts clinical trials for drug candidates.
- Researches novel therapeutic approaches.
- Seeks to address unmet medical needs in GI disorders.
- Aims to improve patient outcomes in GI diseases.
How Does MTCR Make Money?
- Develops and patents novel therapies for gastrointestinal diseases.
- Conducts clinical trials to demonstrate safety and efficacy.
- Seeks regulatory approval from agencies like the FDA.
- May partner with larger pharmaceutical companies for commercialization.
What Industry Does MTCR Operate In?
Metacrine, Inc. operates within the competitive biotechnology industry, which is characterized by high research and development costs, lengthy regulatory approval processes, and intense competition. The market for gastrointestinal disease therapies is substantial, driven by the increasing prevalence of conditions like ulcerative colitis. Metacrine's success depends on its ability to successfully develop and commercialize its lead candidate, MET642, in a market dominated by established pharmaceutical companies and other emerging biotech firms. The company must navigate the complex regulatory landscape and secure sufficient funding to support its clinical development programs.
Who Are MTCR's Key Customers?
- Patients suffering from gastrointestinal diseases, particularly ulcerative colitis.
- Healthcare providers who treat patients with GI disorders.
- Pharmaceutical companies seeking to license or acquire novel therapies.
- Payers (insurance companies) who reimburse for treatment costs.
Company Profile
Metacrine, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in San Diego, US. The company is led by CEO David M. Maggio. MTCR has traded publicly since 2020.
Key Financial Metrics
Return on equity for Metacrine, Inc. stands at -83.5%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -76.6%, showing how much profit it generates from its asset base. A current ratio of 10.15 indicates the company holds enough short-term assets to cover its near-term obligations.
Financial Health
Metacrine, Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -5.64 places it in the distress zone, a signal of elevated financial risk.
MTCR Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence from leadership in Metacrine's future prospects.
- Community sentiment has shifted positively with discussions around potential product advancements gaining traction.
- Analysts are highlighting the company's innovative approach to liver disease treatments, which could position it favorably in a growing market.
- Recent collaborations or partnerships have sparked optimism, indicating potential for enhanced market reach.
Bear Case
- Concerns over the company's financial sustainability persist, as ongoing cash burn rates raise questions among investors.
- Negative sentiment has emerged from some analysts regarding the competitive landscape, suggesting Metacrine may struggle to differentiate its offerings.
- Recent clinical trial results have not met all expectations, leading to skepticism about the efficacy of their key products.
- Overall market volatility has led to a cautious approach among investors, impacting sentiment negatively despite some positive developments.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
MTCR Latest News
No recent news available for MTCR.
Leadership: David M. Maggio
Unknown
David M. Maggio currently manages 10 employees at Metacrine, Inc. Additional background information regarding his career history, education, and previous roles is not available. Further research would be needed to provide a comprehensive profile of his experience and qualifications.
Track Record: Information regarding David M. Maggio's specific achievements, strategic decisions, and company milestones under his leadership at Metacrine, Inc. is not available. Further research would be needed to assess his track record and contributions to the company's progress.
MTCR Healthcare Stock FAQ
What happened to Metacrine, Inc. (MTCR) stock?
Metacrine, Inc. (MTCR) no longer trades on public markets. It was delisted in June 2023. The figures below are historical and are not a current quote.
Can I still buy MTCR shares?
No. MTCR stopped trading on public markets in June 2023, so the shares are not available through a broker. Anything you see quoted for MTCR elsewhere is historical data, not a live market.
Are the figures on this page current?
No. Every number here is the last value recorded before MTCR stopped trading. Nothing on this page updates, and none of it is a current quote.
Why does this page still exist?
Because people still search for what happened to Metacrine, Inc.. An archived profile that states the delisting plainly is more useful than a dead link — provided it is labelled as history, which is what this page does.
What does Metacrine, Inc. do?
Metacrine, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of therapies for gastrointestinal diseases. Their primary focus is on ulcerative colitis, with their lead product candidate, MET642, currently in Phase I clinical trials.
What do analysts say about MTCR stock?
Analyst coverage of Metacrine, Inc. (MTCR) is currently unavailable. Key valuation metrics and growth considerations are difficult to assess without analyst ratings. Investors should conduct their own due diligence and consider the company's financial performance, clinical trial results, and competitive landscape before making any investment decisions. The company's reliance on a single lead candidate and its early-stage clinical development pose inherent risks that should be carefully evaluated.
What are the main risks for MTCR?
Metacrine, Inc. faces several key risks inherent to its business model and industry. Clinical trial failures represent a significant risk, as the company's lead candidate, MET642, may not demonstrate sufficient efficacy or safety in later-stage trials. Regulatory hurdles also pose a risk, as the FDA may not approve MET642 even if clinical trials are successful.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on limited sources.
- CEO information is incomplete.